TY - JOUR
T1 - Amphetamine-induced displacement of [18F] fallypride in striatum and extrastriatal regions in humans
AU - Riccardi, Patrizia
AU - Li, Rui
AU - Ansari, Mohammad Sib
AU - Zald, David
AU - Park, Sohee
AU - Dawant, Benoit
AU - Anderson, Sharlet
AU - Doop, Mikisha
AU - Woodward, Neil
AU - Schoenberg, Evan
AU - Schmidt, Dennis
AU - Baldwin, Ronald
AU - Kessler, Robert
N1 - Funding Information:
Funding for this research was provided by a NIH grant entitled, ‘PET Imaging of Extrastriatal Dopamine Levels’, NIMH 5R01 MH60898-03. We wish to thank Janine Belote, Michelle Costner, and Sarah Moore for technical assistance, and Joann Fields for her excellent assistance in the preparation of this manuscript.
PY - 2006/5
Y1 - 2006/5
N2 - This study examined D-amphetamine (D-AMPH)-induced displacements of [18F] fallypride in striatal and extrastriatal regions and the correlations of these displacements with cognition, affect, and sensation-seeking behavior. In all, 14 normal subjects, six females and eight males (ages 21-32, mean age 25.9 years), underwent positron emission tomography (PET) with [18F]fallypride before and 3 h after a 0.43 mg/kg oral dose of D-AMPH. Levels of dopamine (DA) D2 receptor density were calculated with the reference region method of Lammerstma. Percent displacements in striatal and extrastriatal regions were calculated for the caudate, putamen, ventral striatum, medial thalamus, amygdala, substantia nigra, and temporal cortex. Correlations of changes in cognition, affect, and sensation seeking with parametric images of D-AMPH-induced DA release were computed. Significant displacements were seen in the caudate, putamen, ventral striatum substantia nigra, and temporal cortex with a trend level change in the amygdala. Greatest displacements were seen in striatal subdivisions - 5.6% in caudate, 11.2% in putamen, 7.2% in ventral striatum, and 6.6% in substantia nigra. Lesser decrements were seen in amygdala - 4.4%, temporal cortex - 3.7%, and thalamus - 2.8%. Significant clusters of correlations of regional DA release with cognition and sensation-seeking behavior were observed. The current study demonstrates that [18F]fallypride PET studies using oral D-AMPH (0.43 mg/kg) can be used to study D-AMPH-induced DA release in the striatal and extrastriatal regions in humans, and their relationship with cognition and sensation-seeking behavior.
AB - This study examined D-amphetamine (D-AMPH)-induced displacements of [18F] fallypride in striatal and extrastriatal regions and the correlations of these displacements with cognition, affect, and sensation-seeking behavior. In all, 14 normal subjects, six females and eight males (ages 21-32, mean age 25.9 years), underwent positron emission tomography (PET) with [18F]fallypride before and 3 h after a 0.43 mg/kg oral dose of D-AMPH. Levels of dopamine (DA) D2 receptor density were calculated with the reference region method of Lammerstma. Percent displacements in striatal and extrastriatal regions were calculated for the caudate, putamen, ventral striatum, medial thalamus, amygdala, substantia nigra, and temporal cortex. Correlations of changes in cognition, affect, and sensation seeking with parametric images of D-AMPH-induced DA release were computed. Significant displacements were seen in the caudate, putamen, ventral striatum substantia nigra, and temporal cortex with a trend level change in the amygdala. Greatest displacements were seen in striatal subdivisions - 5.6% in caudate, 11.2% in putamen, 7.2% in ventral striatum, and 6.6% in substantia nigra. Lesser decrements were seen in amygdala - 4.4%, temporal cortex - 3.7%, and thalamus - 2.8%. Significant clusters of correlations of regional DA release with cognition and sensation-seeking behavior were observed. The current study demonstrates that [18F]fallypride PET studies using oral D-AMPH (0.43 mg/kg) can be used to study D-AMPH-induced DA release in the striatal and extrastriatal regions in humans, and their relationship with cognition and sensation-seeking behavior.
KW - Amphetamine challenge
KW - Dopamine
KW - Humans
KW - PET
KW - [F]fallypride
UR - http://www.scopus.com/inward/record.url?scp=33646151160&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646151160&partnerID=8YFLogxK
U2 - 10.1038/sj.npp.1300916
DO - 10.1038/sj.npp.1300916
M3 - Article
C2 - 16237395
AN - SCOPUS:33646151160
VL - 31
SP - 1016
EP - 1026
JO - Neuropsychopharmacology
JF - Neuropsychopharmacology
SN - 0893-133X
IS - 5
ER -